Intravenous immunoglobulin: adverse effects and safe administration

Area of Science:

• Immunology
• Pharmacology
• Nephrology

Background:

• Intravenous immunoglobulin (IVIg) is a widely used therapy for various conditions.
• While generally safe, IVIg administration can lead to adverse effects (AEs).
• Understanding and mitigating these AEs is crucial for patient safety.

Purpose of the Study:

• To review the spectrum of adverse effects associated with IVIg administration.
• To identify risk factors for severe AEs.
• To provide recommendations for preventing and managing IVIg-related complications.

Main Methods:

• Literature review of IVIg adverse events.
• Analysis of risk factors for renal failure, thromboembolic events, and aseptic meningitis.
• Summary of current management strategies for IVIg AEs.

Main Results:

• Most IVIg AEs are mild and transient, including headache, fever, and malaise.
• Serious AEs like acute renal failure and thromboembolic events are rare but significant.
• Risk factors for renal and thromboembolic events include dehydration, advanced age, diabetes, and rapid infusion rates.

Conclusions:

• IVIg is a valuable therapeutic agent with a manageable safety profile.
• Careful patient selection, hydration, slow infusion rates, and appropriate product choice can minimize risks.
• Vigilance for AEs and prompt management are essential for optimal patient outcomes.